Article thumbnail

Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease

By Wenjun Li, Liu Zheng, Chunjun Sheng, Xiaoyun Cheng, Liu Qing and Shen Qu
Topics: Review
Publisher: BioMed Central
OAI identifier: oai:pubmedcentral.nih.gov:3088890
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. (1999). AJ: Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology
  2. (2008). Beyond insulin resistance: Innate immunity in nonalcoholic steatohepatitis. Hepatology
  3. (2008). Contribution of de novo fatty acid synthesis to hepatic steatosis and insulin resistance: lessons from genetically engineered mice.
  4. (2006). Czaja MJ: JNK1 but not JNK2 promotes the development of steatohepatitis in mice. Hepatology
  5. (2001). Del Vecchio Blanco C: Non-alcoholic fatty liver disease in an area of southern Italy: main clinical, histological, and pathophysiological aspects.
  6. (2005). Diehl AM: Role of inflammation in nonalcoholic steatohepatitis. Curr Opin Gastroenterol
  7. (2008). Fatty liver and insulin resistance: not always linked. Trans Am Clin Climatol Assoc
  8. (2001). GB: Effects of pentoxifylline on the different steps during adhesion and transendothelial migration of flowing neutrophils. Cell Biochem Funct
  9. (2003). GI: Cellular mechanism of insulin resistance: potential links with inflammation.
  10. (2003). Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis. Gastroenterology
  11. (2006). Hwang DH: The modulation of inflammatory gene expression by lipids: mediation through Toll-like receptors. Mol Cell
  12. (2006). Inflammation and insulin resistance.
  13. (2008). Lim SG: A randomized controlled pilot study of Pentoxifylline in patients with non-alcoholic steatohepatitis (NASH). Hepatol Int
  14. (2004). Lindor KD: A pilot trial of pentoxifylline in nonalcoholic steatohepatitis.
  15. (2005). Lindor KD: Nonalcoholic fatty liver disease. CMAJ
  16. (2006). Lipid Metabolism and Liver Inflammation. II. Fatty liver disease and fatty acid oxidation.
  17. (2010). Newsome PN: Pathogenesis of non-alcoholic fatty liver disease. QJM
  18. (2008). Nieto-Vazquez I: Insulin resistance induced by tumor necrosis factor-alpha in myocytes and brown adipocytes.
  19. (2005). Nonalcoholic steatohepatitis: pathologic features and differential diagnosis. Semin Diagn Pathol
  20. (2007). Pathology of nonalcoholic fatty liver disease.
  21. (2001). PE: Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology
  22. (2005). Pentoxifylline/Nonalcoholic Steatohepatitis (NASH) Study: The Effect of Pentoxifylline on NASH. Clinical trials.gov
  23. (2005). Sahin K: Levels of serum hyaluronic acid, TNF-alpha and IL-8 in patients with nonalcoholic steatohepatitis. Hepatogastroenterology
  24. (2006). Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int
  25. (2000). Shakil O: Pentoxifylline improves short-term survival in severe acute alcoholic hepatitis: a double-blind, placebo-controlled trial. Gastroenterology
  26. (2004). Shulman GI: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. Biol Chem
  27. (2007). SK: Beneficial effects of pentoxifylline on hepatic steatosis, fibrosis and necroinflammation in patients with non-alcoholic steatohepatitis.
  28. (2004). Sung JJ: Clinical and histological features of non-alcoholic fatty liver disease in Hong Kong Chinese. Aliment Pharmacol Ther
  29. (2003). The comparative effects of pentoxifylline and ursodeoxycholic acid on IL-1β, Il-6, Il-8 and TNF-α levels in nonalcoholic fatty liver.
  30. (2007). Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis
  31. (1999). Tuchweber B: Effect of pentoxifylline on early proliferation and phenotypic modulation of fibrogenic cells in two rat models of liver fibrosis and on cultured hepatic stellate cells.
  32. (2004). Tumor necrosis factor and its potential role in insulin resistance and nonalcoholic fatty liver disease. Clin Liver Dis
  33. (2007). Udomsubpayakul U: Pentoxifylline for Treatment of Nonalcoholic Fatty Liver Disease (NAFLD): A Randomized, PlaceboControlled Study.